ES2173846T3 - Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2. - Google Patents

Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.

Info

Publication number
ES2173846T3
ES2173846T3 ES00305372T ES00305372T ES2173846T3 ES 2173846 T3 ES2173846 T3 ES 2173846T3 ES 00305372 T ES00305372 T ES 00305372T ES 00305372 T ES00305372 T ES 00305372T ES 2173846 T3 ES2173846 T3 ES 2173846T3
Authority
ES
Spain
Prior art keywords
halo
alkyl
substituted
biciclocarbonil
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00305372T
Other languages
English (en)
Inventor
Shigeo Hayashi
Rodney William Stevens
Kazunari Nakao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2173846T3 publication Critical patent/ES2173846T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula **fórmula** o las sales farmacéuticamente aceptables del mismo, en la que A es alquileno C1-6 o NR1 -; Z es C(=L)R2, o SO2R3; U es CH o N; W e Y se seleccionan independientemente entreCH2-, O, S y N-R1; m es 1, 2 ó 3; q y r son, independientemente, 0, 1 ó 2; X se selecciona independientemente a partir de halógeno, alquilo C1-4, alquilo C1-4 sustituido con halógeno, hidroxi, alcoxi C1-4, alcoxi C1-4 sustituido con halógeno, alquil C1-4-tio, nitro, amino, mono o di-(alquil C1-4)amino y ciano; n es 0, 1, 2, 3 ó 4; L es oxígeno o azufre; R1 es hidrógeno o alquilo C1-4; R2 es hidroxi, alquilo C1-6, alquilo C1-6 sustituido con halógeno, alcoxi C1-6, alcoxi C1-6 sustituido con halógeno, cicloalcoxilo C3-7, alquil-C1-4 (cicloalcoxil C3- 7), -N-R4R5, alquil C1-4 -fenil-O- o fenil-O-, estando dicho fenilo sustituido opcionalmente con 1 a 5 sustituyentes seleccionados independientemente a partir de halógeno, alquilo C1-4, hidroxi, alcoxi C1-4 y nitro; R3 es un alquilo C1-6 oun alquilo C1-6 sustituido con halógeno; y R4 y R5 se seleccionan independientemente entre hidrógeno, alquilo C1-6 y alquilo C1-6 sustituido con halógeno.
ES00305372T 1999-07-02 2000-06-26 Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2. Expired - Lifetime ES2173846T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB99/01243 1999-07-02

Publications (1)

Publication Number Publication Date
ES2173846T3 true ES2173846T3 (es) 2002-11-01

Family

ID=11004872

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00305372T Expired - Lifetime ES2173846T3 (es) 1999-07-02 2000-06-26 Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.

Country Status (11)

Country Link
US (1) US6303628B1 (es)
EP (1) EP1065204B1 (es)
JP (1) JP3333179B2 (es)
AT (1) ATE215945T1 (es)
BR (1) BR0002936A (es)
CA (1) CA2313122C (es)
DE (1) DE60000120T2 (es)
DK (1) DK1065204T3 (es)
ES (1) ES2173846T3 (es)
MX (1) MXPA00006605A (es)
PT (1) PT1065204E (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20030119895A1 (en) * 1998-12-23 2003-06-26 Pharmacia Corporation Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US20030203956A1 (en) * 1998-12-23 2003-10-30 Masterrer Jaime L. Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
SI1438289T1 (es) * 2001-09-27 2005-08-31 Hoffmann La Roche
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20040034083A1 (en) * 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
CA2482510A1 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Monotherapy for the treatment of parkinson`s disease with cyclooxygenase-2 (cox 2) inhibitor(s)
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
EP1572678A4 (en) * 2002-12-19 2008-05-07 Elan Pharm Inc SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
EP1708718A1 (en) 2004-01-22 2006-10-11 Pfizer Limited Triazole derivatives which inhibit vasopressin antagonistic activity
JP2007534740A (ja) * 2004-04-28 2007-11-29 ファイザー・インク バソプレッシンＶ１ａ受容体の阻害剤としての３−ヘテロシクリル−４−フェニル−トリアゾール誘導体
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
EA017171B1 (ru) 2006-12-22 2012-10-30 Рекордати Айерленд Лимитед КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
BR112014026305A2 (pt) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
JP6177768B2 (ja) 2012-04-24 2017-08-09 中外製薬株式会社 ベンズアミド誘導体
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
JP6820854B2 (ja) * 2015-01-18 2021-01-27 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｍａｐ４ｋ４（ｈｇｋ）インヒビター
US9808443B1 (en) 2016-11-28 2017-11-07 King Saud University Cyclooxygenase inhibitors
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284862A (en) * 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
IL120724A0 (en) 1995-09-01 1997-08-14 Lilly Co Eli Indolyl neuropeptide Y receptor antagonists
AP9801302A0 (en) * 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
AP869A (en) * 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.

Also Published As

Publication number Publication date
CA2313122C (en) 2004-08-24
EP1065204A4 (en) 2000-11-15
DK1065204T3 (da) 2002-07-22
JP2001031677A (ja) 2001-02-06
CA2313122A1 (en) 2001-01-02
EP1065204A1 (en) 2001-01-03
JP3333179B2 (ja) 2002-10-07
EP1065204B1 (en) 2002-04-10
DE60000120D1 (de) 2002-05-16
BR0002936A (pt) 2001-04-03
PT1065204E (pt) 2002-08-30
US6303628B1 (en) 2001-10-16
ATE215945T1 (de) 2002-04-15
DE60000120T2 (de) 2002-08-14
MXPA00006605A (es) 2004-12-09

Similar Documents

Publication Publication Date Title
ES2173846T3 (es) Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.
SE9904508D0 (sv) New compounds
SE9903760D0 (sv) New compounds
PT1104760E (pt) Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
BR9904998B1 (pt) derivados de hidroxamida do ácido 5-oxo-pirrolidina-2-carboxìlico e composição farmacêutica.
ES2191260T3 (es) Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos.
NO20014925L (no) Farmasöytiske forbindelser
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
PL359415A1 (en) Oxadiazole derivatives having anticancer effects
IL134894A (en) 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them
AU2003223340A8 (en) Certain pharmaceutically useful substituted aminoalkyl heterocycles
PT1106614E (pt) Compostos de 1,4-dihidropiridina substituidos com heteroarilos de 5 membros como antagonistas de bradiquinina
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
SI1578741T1 (sl) Aromatske spojine kot protivnetna imunomodulatorna in antiproliferativna sredstva
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
ATE258934T1 (de) Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe
NO20006065D0 (no) Cyanoiminokinoksalinderivater
PT1065206E (pt) Compostos de tetrazolilalquilindole e como agentes anti-inflamatorios e analgesicos
ECSP993005A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1065204

Country of ref document: ES